Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Jaewon | - |
dc.contributor.author | Chung, Jong-Won | - |
dc.contributor.author | Jang, Hyun-Soon | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Hong, Keun-Sik | - |
dc.contributor.author | Bang, Oh Young | - |
dc.contributor.author | Kim, Gyeong-Moon | - |
dc.contributor.author | Seo, Woo-Keun | - |
dc.date.accessioned | 2022-02-26T21:41:10Z | - |
dc.date.available | 2022-02-26T21:41:10Z | - |
dc.date.created | 2022-01-20 | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 2047-4873 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/137061 | - |
dc.description.abstract | Aims Lowering the low-density lipoprotein cholesterol level reduces the risk of stroke, but it has not been clear whether the stroke risk would continuously decrease by lowering low-density lipoprotein cholesterol to a very low level. The purpose of this study was to evaluate the association between achieved low-density lipoprotein cholesterol levels and stroke risk. Methods and results A systematic search of MEDLINE, EMBASE and Cochrane Library databases was conducted to identify randomised controlled trials that tested cholesterol-lowering pharmacological therapies and reported both achieved low-density lipoprotein cholesterol levels and stroke outcomes. A meta-regression analysis was conducted to assess the linear association between the achieved low-density lipoprotein cholesterol levels and stroke risk. In addition, we evaluated pooled estimates of low-density lipoprotein cholesterol-lowering effect stratified by achieved low-density lipoprotein cholesterol levels of active arms. A total of 222,149 participants in 23 trials (52 arms of 26 studies) were included. The meta-regression analysis showed that each 1 mmol/L decrease in the achieved low-density lipoprotein cholesterol level (down to 0.78 mmol/L) was associated with a significant reduction of 23.5% (slope 0.235, 95% confidence interval 0.007-0.464, P = 0.044) in stroke risk. Irrespective of achieved low-density lipoprotein cholesterol levels in the active arms, the effects of lowering the low-density lipoprotein cholesterol level on stroke risk were significant and consistent (test for subgroup difference, P = 0.23, I-2 = 31%). However, there was no significant increase in haemorrhagic stroke risk with lower achieved low-density lipoprotein cholesterol levels. Conclusion In this meta-analysis of randomised controlled trials, the stroke risk monotonically reduced with lowering of low-density lipoprotein cholesterol to very low levels. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.subject | HIGH-DOSE ATORVASTATIN | - |
dc.subject | HYPERTENSIVE PATIENTS | - |
dc.subject | LOWERING TREATMENT | - |
dc.subject | CARDIAC OUTCOMES | - |
dc.subject | LDL CHOLESTEROL | - |
dc.subject | CORONARY | - |
dc.subject | HEART | - |
dc.subject | PREVENTION | - |
dc.subject | EFFICACY | - |
dc.subject | DISEASE | - |
dc.title | Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.identifier.doi | 10.1177/2047487319830503 | - |
dc.identifier.scopusid | 2-s2.0-85061981631 | - |
dc.identifier.wosid | 000693200600030 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, v.28, no.8, pp.905 - 916 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | - |
dc.citation.title | EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | - |
dc.citation.volume | 28 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 905 | - |
dc.citation.endPage | 916 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | HIGH-DOSE ATORVASTATIN | - |
dc.subject.keywordPlus | HYPERTENSIVE PATIENTS | - |
dc.subject.keywordPlus | LOWERING TREATMENT | - |
dc.subject.keywordPlus | CARDIAC OUTCOMES | - |
dc.subject.keywordPlus | LDL CHOLESTEROL | - |
dc.subject.keywordPlus | CORONARY | - |
dc.subject.keywordPlus | HEART | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | LDL-cholesterol | - |
dc.subject.keywordAuthor | statin | - |
dc.subject.keywordAuthor | PCSK9 inhibitor | - |
dc.subject.keywordAuthor | meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.